OQS
CRBP icon

Occudo Quantitative Strategies’s Corbus Pharmaceuticals CRBP Stock Holding History

Occudo Quantitative Strategies’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,073
Closed -$72.2K – 674
2025
Q1 		$72.2K Buy
+13,073
New +$115K 0.01% 613

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Occudo Quantitative Strategies's CRBP Position: Q2 2025 in Review

Occudo Quantitative Strategies sold out of Corbus Pharmaceuticals (CRBP) in Q2 2025, closing a stake of 13,073 shares — an estimated $72.2K sold.

Occudo Quantitative Strategies first reported a position in CRBP in Q1 2025 and held it in 1 quarter. The position peaked at $72.2K in Q1 2025. 80 funds tracked by Wall St. Rank hold CRBP as of Q2 2025.

  • Occudo Quantitative Strategies reported no remaining Corbus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 13,073 Corbus Pharmaceuticals shares in Q2 2025, an estimated $72.2K.
  • Occudo Quantitative Strategies first reported a position in Corbus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Corbus Pharmaceuticals position peaked at $72.2K in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.